Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian G Feagan

Showing results (91-100 of 464) with videos related to

Pageof 47
Sort By:
Journal of Medical Economics|August 28, 2014
Healthcare costs for Crohn's disease patients treated with infliximab: a propensity weighted comparison of the effects of treatment adherenceBrian G Feagan, Chris M Kozma, Terra L Slaton, et al.
Drugs|June 2, 2023
Targeting IL-23 for IBD: Rationale and Progress to DateSudheer K Vuyyuru, Lisa M Shackelton, Jurij Hanzel, et al.
Journal of Medical Economics|March 29, 2014
Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapyGeorge J Wan, Chris M Kozma, Terra L Slaton, et al.
The Cochrane Database of Systematic Reviews|August 8, 2014
Methotrexate for induction of remission in refractory Crohn's diseaseJohn W D McDonald, Yongjun Wang, David J Tsoulis, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 7, 2022
Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative ColitisParambir S Dulai, Brian G Feagan, Bruce E Sands, et al.
Clinical Pharmacology and Therapeutics|March 15, 2024
Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug-Drug InteractionsJie Shao, Marion Vetter, An Vermeulen, et al.
Drugs|March 2, 2017
Erratum to: Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical OverviewPieter Hindryckx, Gregor Novak, Niels Vande Casteele, et al.
The American Journal of Gastroenterology|August 10, 2005
Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trialsWilliam J Sandborn, Robert Löfberg, Brian G Feagan, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 26, 2020
Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel DiseaseAhmed Almradi, Jurij Hanzel, Rocio Sedano, et al.
Drugs|February 25, 2017
Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical OverviewPieter Hindryckx, Gregor Novak, Niels Vande Casteele, et al.
Pageof 47

Showing results (91-100 of 464) with videos related to

Sort By:
Pageof 47
Journal of Medical Economics|August 28, 2014
Healthcare costs for Crohn's disease patients treated with infliximab: a propensity weighted comparison of the effects of treatment adherenceBrian G Feagan, Chris M Kozma, Terra L Slaton, et al.
Drugs|June 2, 2023
Targeting IL-23 for IBD: Rationale and Progress to DateSudheer K Vuyyuru, Lisa M Shackelton, Jurij Hanzel, et al.
Journal of Medical Economics|March 29, 2014
Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapyGeorge J Wan, Chris M Kozma, Terra L Slaton, et al.
The Cochrane Database of Systematic Reviews|August 8, 2014
Methotrexate for induction of remission in refractory Crohn's diseaseJohn W D McDonald, Yongjun Wang, David J Tsoulis, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 7, 2022
Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative ColitisParambir S Dulai, Brian G Feagan, Bruce E Sands, et al.
Clinical Pharmacology and Therapeutics|March 15, 2024
Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug-Drug InteractionsJie Shao, Marion Vetter, An Vermeulen, et al.
Drugs|March 2, 2017
Erratum to: Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical OverviewPieter Hindryckx, Gregor Novak, Niels Vande Casteele, et al.
The American Journal of Gastroenterology|August 10, 2005
Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trialsWilliam J Sandborn, Robert Löfberg, Brian G Feagan, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 26, 2020
Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel DiseaseAhmed Almradi, Jurij Hanzel, Rocio Sedano, et al.
Drugs|February 25, 2017
Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical OverviewPieter Hindryckx, Gregor Novak, Niels Vande Casteele, et al.
Pageof 47